Pure Global
NCT06215638

An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

Peking Union Medical College Hospital·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Rheumatoid Arthritis
Drug/Device/Intervention
Bortezomib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking Union Medical College Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2023
End date
Dec 30, 2024
Enrollment
30 participants
Primary outcome

ACR20

Summary

The goal of this prospective single-arm open-label trial is to learn about efficacy and
 safety of Bortezomib in treating patients with difficult-to-treat rheumatoid arthritis. The
 main questions it aims to answer are:
 
 - Is Bortezomib an effective treatment option for patients with difficult-to-treat
 rheumatoid arthritis?
 
 - Is Bortezomib safe enough in treating patients with difficult-to-treat rheumatoid
 arthritis?
 
 Participants will:
 
 - Receive Bortezomib 2 mg per week subcutaneously for twelve weeks in total.
 
 - Follow-up at weeks 4, 12, and 24, while biosamples will be collected.

ICD-10 classifications
Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06215638
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06215638 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking Union Medical College Hospital and is currently Recruitment Completed. The study focuses on Rheumatoid Arthritis. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.